Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
“Your story matters.”
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
“For example, a number of oncogenic signalling pathways all seem to converge on a limited set of nuclear transcription factor”
BackgroundRevisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
A census of human transcription factors: function, expression and evolution
Vaquerizas, J. M., Kummerfeld, S. K., Teichmann, S. A., & Luscombe, N. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2538 · Cited by 1,573
“TFs and human diseases Transcriptional misregulation has been associated with a diverse set of diseases, including cancer and developmental syndrome”
BackgroundEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
“Once activated in malignant or immune cells, STAT3 can induce the expression of a subset of genes whose products are important for further STAT3 activation, including IL-6, IL-22, EGF, IL-23 and IL-10 [52,53] as well as STAT3-dependent induction of cell surface growth factor and cytokine receptors (EGFR, c-Met, IL-23R…”
BackgroundReactive oxygen species in tumor progression
Storz, P. (2005) · Frontiers in Bioscience · doi:10.2741/1667 · Cited by 957
“NF-κB almost always drives transcription in association with other transcription factors (156).”
BackgroundTargeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Valavanidis, A., Vlachogianni, T., Fiotakis, K., & Loridas, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10093886 · Cited by 910
Direct inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
PVT1 dependence in cancer with MYC copy-number increase
Tseng, Y.-Y., Moriarity, B. S., Gong, W., Akiyama, R., Tiwari, A., Kawakami, H., Ronning, P., Reuland, B., Guenther, K., Beadnell, T. C., et al. (2014) · Nature · doi:10.1038/nature13311 · Cited by 722
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis
Roman-Blas, J. A., & Jimenez, S. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.04.008 · Cited by 688
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Recognition of the DNA minor groove by pyrrole-imidazole polyamides
Dervan, P. B., & Edelson, B. S. (2003) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(03)00081-2 · Cited by 633
Axis of evil: molecular mechanisms of cancer metastasis
Bogenrieder, T., & Herlyn, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206757 · Cited by 593
“Target genes of TCF/b-catenin that could be relevant for tumor progression include the protooncogenes c-Myc and cyclin D1 (Polakis, 2000; Barth and Nelson, 2002; Darnell, 2002).”
BackgroundXu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., Gritsko, T., Turkson, J., Kay, H., Semenza, G. L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208719 · Cited by 576
Thymoquinone: Potential cure for inflammatory disorders and cancer
Woo, C. C., Kumar, A. P., Sethi, G., & Tan, K. H. B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.09.029 · Cited by 541
“STAT3 is often constitutively activated in various carcinomas and interferes at different levels of tumorigenesis [36].”
BackgroundEchinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
“Therefore, transcription factors may represent attractive targets for development of therapeutics (1).”
BackgroundTargeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 515
Stimulus Specificity of Gene Expression Programs Determined by Temporal Control of IKK Activity
Werner, S. L., Barken, D., & Hoffmann, A. (2005) · Science · doi:10.1126/science.1113319 · Cited by 505
Sp transcription factor family and its role in cancer
Safe, S., & Abdelrahim, M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.006 · Cited by 500
“Transcription factors are now recognized as targets for development of new anticancer drugs [113], and this review outlines the important role of Sp-dependent gene expression in tumour development, growth and metastasis.”
BackgroundSTAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
“In cancer, many oncogenic changes deregulate signal transduction pathways (Darnell, 2002).”
BackgroundThe biology and treatment of plasmablastic lymphoma
Castillo, J. J., Bibas, M., & Miranda, R. N. (2015) · Blood · doi:10.1182/blood-2014-10-567479 · Cited by 472
“TheMYC gene has been considered untargetable, given its lack of a binding domain.(68) MYC heterodimerizes with the transcription factor Max, but the tridimensional structure of this complexdoes not permit the positioningof smallmolecules.”
BackgroundSuppression of cancer relapse and metastasis by inhibiting cancer stemness
Li, Y., Rogoff, H. A., Keates, S., Gao, Y., Murikipudi, S., Mikule, K., Leggett, D., Li, W., Pardee, A. B., & Li, C. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424171112 · Cited by 458
“Targeting Stat3 is expected to trigger a cascade of down-regulation of stemness genes, via direct or indirect mechanisms (32).”
BackgroundLuker, K. E., Smith, M. C. P., Luker, G. D., Gammon, S. T., Piwnica-Worms, H., & Piwnica-Worms, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404041101 · Cited by 439
Molecular Link Mechanisms between Inflammation and Cancer
B. Vendramini-Costa, D., & E. Carvalho, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802083707 · Cited by 417
Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 415
Sun, M., Estrov, Z., Ji, Y., Coombes, K. R., Harris, D. H., & Kurzrock, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2272 · Cited by 412
“Transcription factors such as SP1 are now recognized targets for the development of new anticancer drugs (51, 52), including drugs for pancreatic cancer (53).”
BackgroundAdvances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
“ber of human cancers (12), we explored their role in the sup-”
BackgroundFeng, R., Lu, Y., Bowman, L. L., Qian, Y., Castranova, V., & Ding, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503347200 · Cited by 389
Dysregulated molecular networks in head and neck carcinogenesis
Molinolo, A. A., Amornphimoltham, P., Squarize, C. H., Castilho, R. M., Patel, V., & Gutkind, J. S. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2008.07.011 · Cited by 385
“To date, seven STAT family members have been identified, STATs 1, 2, 3, 4, 5a, 5b and 6, which participate in the transcription of genes involved in immune responses, growth, and cell fate decisions (83).”
BackgroundKortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
The Mediator complex and transcription regulation
Poss, Z. C., Ebmeier, C. C., & Taatjes, D. J. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.840259 · Cited by 364
Signaling Pathways in Cancer and Embryonic Stem Cells
Dreesen, O., & Brivanlou, A. H. (2007) · Stem Cell Reviews · doi:10.1007/s12015-007-0004-8 · Cited by 357
“Tyrosine phosphorylated STATs form homodimers, shuttle to the nucleus and participate in transcriptional regulation of a variety of genes [13, 14].”
BackgroundChan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421032 · Cited by 356
“First, targeting of Stat3 as an anticancer therapy is clearly an important goal (50); in addition, targeting of Stat3 together with DNA-damaging chemotherapies may specifically sensitize cancer cells to apoptosis.”
BackgroundLeptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance
Sahu, A. (2003) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2003.10.001 · Cited by 355
“Furthermore, STAT3 transcriptional activity can be regulated by other factors (co-activator), such as p300/CBP (cAMP response element binding protein-binding protein) and steroid receptor co-activators 1 (NcoA/SRC1a) [77,112,113,254].”
BackgroundAn overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 344
“Signal teins mediate transducer responses and activator to cytokines of transcription and growth (STAT) factors pro- (1).”
BackgroundInfluentialPham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., et al. (2005) · Nature Medicine · doi:10.1038/nm1282 · Cited by 308
“Our evidence that reduction of Stat3 hyperactivation in gp130 Y757F/Y757F Stat3 +/− mice suppressed adenoma formation without having an impact on the myriad physiological Stat3 responses during development, furthermore genetically validates Stat3 signaling as a potential therapeutic target for a variety of epithelial…”
BackgroundValidating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
“For these reasons, increasing attention is being paid to targeting these STATs for the treatment of cance”
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00120 · Cited by 296
“Phosphorylated STATs form homodimers, localize to the nucleus, and regulate genes associated with apoptosis and proliferation (Darnell, 2002).”
BackgroundIndirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells
Nam, S., Buettner, R., Turkson, J., Kim, D., Cheng, J. Q., Muehlbeyer, S., Hippe, F., Vatter, S., Merz, K.-H., Eisenbrand, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409467102 · Cited by 294
Caldwell, R. B., Bartoli, M., Behzadian, M. A., El‐Remessy, A. E. B., Al‐Shabrawey, M., Platt, D. H., & Caldwell, R. W. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.415 · Cited by 293
Choose your partners: dimerization in eukaryotic transcription factors
Amoutzias, G. D., Robertson, D. L., Van de Peer, Y., & Oliver, S. G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.02.002 · Cited by 289
Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J., & Jove, R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0268 · Cited by 283
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
“STAT3, like other STAT family proteins, contains a dimerization domain at the N-terminus, a coiled-coil domain for protein-protein interactions, a central DNA binding domain, an SH2 domain for the recruitment to receptor, a conserved tyrosine residue at position 705 (Tyr-705), and a C-terminus encoding the transcripti…”
BackgroundTargeting STAT3 affects melanoma on multiple fronts
Kortylewski, M., Jove, R., & Yu, H. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1580-1 · Cited by 280
“Because a wide array of oncogenic/angiogenic proteins converge upon a limited set of nuclear transcription factors, the final ‘switches’ determining gene expression patterns and ultimately leading to malignancy [139], targeting a single transcription factor such as STAT3 potentially neutralizes the oncogenic potential…”
BackgroundProtein disulfide isomerase: a promising target for cancer therapy
Xu, S., Sankar, S., & Neamati, N. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.017 · Cited by 278
Targeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Aggarwal, S., Takada, Y., Singh, S., Myers, J. N., & Aggarwal, B. B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20333 · Cited by 274
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 265
NF-κB: tumor promoter or suppressor?
Perkins, N. D. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2003.12.004 · Cited by 261
Kaempferol, a potential cytostatic and cure for inflammatory disorders
Rajendran, P., Rengarajan, T., Nandakumar, N., Palaniswami, R., Nishigaki, Y., & Nishigaki, I. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.011 · Cited by 259
“differentiation, proliferation, apoptosis, angiogen esis, metastasis, and immune responses [49-53].”
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255
Leslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y. B., Paz, K., Darnell, J. E., Albanese, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2203 · Cited by 285
“Deregulated expression of transcription factors can mediate oncogenesis through differential gene expression (41).”
Diaz, N., Minton, S., Cox, C., Bowman, T., Gritsko, T., Garcia, R., Eweis, I., Wloch, M., Livingston, S., Seijo, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1749 · Cited by 242
“Our present study provides support for the development of small molecule inhibitors of Stat3 as well as those of Src kinase for cancer therapeutics (3, 12, 50).”
BackgroundTF-PROTACs Enable Targeted Degradation of Transcription Factors
Liu, J., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03852 · Cited by 247
Pathak, A. K., Bhutani, M., Nair, A. S., Ahn, K. S., Chakraborty, A., Kadara, H., Guha, S., Sethi, G., & Aggarwal, B. B. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0348 · Cited by 235
“proteins have been shown to play an important role in tumor cell survival and proliferation (1).”
BackgroundIdentification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., & Ding, K. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100146z · Cited by 234
Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., Pandit, B., Ihnat, M. A., Shenoy, S. S., Kulp, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2468 · Cited by 234
“cancers feature aberrantly activated STAT3 (3); approaches that selectively target constitutive STAT3 signaling have been shown to be effective at inhibiting cancer-associated processes and cancer cell viability (34, 41); and curcumin, a natural plant polyphenol, displays some capacity for inhibiting STAT3 without the…”
Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc
Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 229
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Defining the sequence-recognition profile of DNA-binding molecules
Warren, C. L., Kratochvil, N. C. S., Hauschild, K. E., Foister, S., Brezinski, M. L., Dervan, P. B., Phillips, G. N., & Ansari, A. Z. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509843102 · Cited by 230
Nanopore Technology and Its Applications in Gene Sequencing
Lin, B., Hui, J., & Mao, H. (2021) · Biosensors · doi:10.3390/bios11070214 · Cited by 228
“In cells, the majority of oncogenes and tumor suppressor genes encode TF [65,77].”
BackgroundChromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Therapeutic Strategies to Inhibit MYC
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 222
Ember, S. W. J., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., & Schönbrunn, E. (2014) · ACS Chemical Biology · doi:10.1021/cb500072z · Cited by 221
Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition
Gormally, M. V., Dexheimer, T. S., Marsico, G., Sanders, D. A., Lowe, C., Matak-Vinković, D., Michael, S., Jadhav, A., Rai, G., Maloney, D. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6165 · Cited by 224
“EMSA was chosen as an orthogonal assay to further evaluate FDI-(1-16) in dose response.”
BackgroundMethodA transcription factor atlas of directed differentiation
Joung, J., Ma, S., Tay, T., Geiger-Schuller, K. R., Kirchgatterer, P. C., Verdine, V. K., Guo, B., Arias-Garcia, M. A., Allen, W. E., Singh, A., et al. (2023) · Cell · doi:10.1016/j.cell.2022.11.026 · Cited by 219
Dysregulation of the basal RNA polymerase transcription apparatus in cancer
Bywater, M. J., Pearson, R. B., McArthur, G. A., & Hannan, R. D. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3496 · Cited by 222
Leduc, A.-M., Trent, J. O., Wittliff, J. L., Bramlett, K. S., Briggs, S. L., Chirgadze, N. Y., Wang, Y., Burris, T. P., & Spatola, A. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934759100 · Cited by 222
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
Olenyuk, B. Z., Zhang, G.-J., Klco, J. M., Nickols, N. G., Kaelin, W. G., & Dervan, P. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407617101 · Cited by 219
Germain, D., & Frank, D. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2491 · Cited by 220
Prusty, B. K., & Das, B. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.20668 · Cited by 218
Shukla, S., MacLennan, G. T., Fu, P., Patel, J., Marengo, S. R., Resnick, M. L., & Gupta, S. (2004) · Neoplasia · doi:10.1593/neo.04112 · Cited by 217
“apy and radiation therapy [51,52].”
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Death receptors and melanoma resistance to apoptosis
Ivanov, V. N., Bhoumik, A., & Ronai, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206456 · Cited by 211
Wyce, A., Ganji, G., Smitheman, K. N., Chung, C.-W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072967 · Cited by 206
“Despite the well-established role of MYC family proteins in driving cancer cell growth, no direct MYC-targeted therapeutic agent has advanced to clinical studies [20,23].”
BackgroundHirsch, F. R., Scagliotti, G. V., Langer, C. J., Varella-Garcia, M., & Franklin, W. A. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00137-5 · Cited by 208
STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers
WANG, X., CROWE, P. J., GOLDSTEIN, D., & YANG, J.-L. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1568 · Cited by 203
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 202
“This perhaps is due to the difficulty of targeting the extended protein-protein interface defined by the heterodimer and the absence of a defined ligand-binding domain (14).”
BackgroundCapsaicin Is a Novel Blocker of Constitutive and Interleukin-6–Inducible STAT3 Activation
Bhutani, M., Pathak, A. K., Nair, A. S., Kunnumakkara, A. B., Guha, S., Sethi, G., & Aggarwal, B. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2575 · Cited by 197
Roles and Regulation of Stat Family Transcription Factors in Human Breast Cancer
Clevenger, C. V. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63403-7 · Cited by 197
STAT3 Ubiquitylation and Degradation by Mumps Virus Suppress Cytokine and Oncogene Signaling
Ulane, C. M., Rodriguez, J. J., Parisien, J.-P., & Horvath, C. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6385-6393.2003 · Cited by 193
Glycogen synthase kinase 3 beta: can it be a target for oral cancer
Mishra, R. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-144 · Cited by 190
“Alteration of the transcriptional machinery is common in neoplastic diseases, including oral cancer [22,23].”
BackgroundNickols, N. G., & Dervan, P. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704217104 · Cited by 189
STAT3 and apoptosis challenges in cancer
Fathi, N., Rashidi, G., Khodadadi, A., Shahi, S., & Sharifi, S. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.121 · Cited by 187
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.